Sangart gains $50M in sixth round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
Sangart
|
$50M
|
Leucadia National Corporation |
The money will be used to advance two large-scale Phase III clinical trials of Sangart's lead product candidate, Hemospan, a hemoglobin-based oxygen carrier designed to serve as an alternative to blood transfusions. |
|
Affimed Therapeutics
|
$32M
|
BioMedInvest, OrbiMed Advisors and Life Sciences Partners |
Much of that money will be used to finance the clinical development of its leading programs for Hodgkin's disease and non-Hodgkin's Lymphoma. |
|
Protemix
|
$14.5M
|
Novartis Venture Fund and NovaQuest |
Proceeds from the financing will be used to advance the clinical development of Protemix's lead product, PX811019, as a potential treatment for diabetic heart failure |